A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

Summary

This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Measles
• Measles-Mumps-Rubella+Chickenpox Vaccine

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

15 months to 6 years

Sex

All

Healthy volunteers

Accepted

Sponsor

GlaxoSmithKline

Last updated on ClinicalTrials.gov

July 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites